Cancer Protein TIPE Hijacks Immune Cells to Fuel Colorectal Tumor Growth

Inside every solid tumor, a silent negotiation is underway between malignant cells and the immune cells that surround them. In colorectal cancer, one of the most common malignancies worldwide, that negotiation often ends with the immune system standing down. A new study published in Cancer Immunology, Immunotherapy has now traced one of the molecular conversations responsible, revealing how a protein called TIPE, produced abundantly in colorectal tumors, persuades macrophages, the immune system’s versatile first responders, to switch allegiance and actively support tumor growth. The findings, reported by a team of researchers based at Xiamen University and collaborating institutions in China, map a signaling chain that runs from TIPE through a decoy receptor known as DcR3 and ultimately rewires macrophage behavior within the tumor microenvironment.

The central player, tumor necrosis factor alpha-induced protein 8, or TIPE, has attracted growing attention in cancer research because of its role in regulating inflammatory and immune signaling pathways. The research team began by examining colorectal cancer tissue samples and found that TIPE expression was elevated in tumor tissue. More strikingly, the abundance of TIPE correlated positively with the levels of characteristic markers of M2 macrophages, including CD206, CD163, and the anti-inflammatory cytokine interleukin-10. This correlation mattered because macrophages are not a uniform population. In simplified terms, M1 macrophages tend to mount inflammatory attacks against tumor cells, while M2 macrophages promote tissue repair, wound healing, and, unfortunately for patients, tumor progression and immunosuppression. A tumor rich in M2 macrophages is a tumor that has effectively recruited the body’s own repair machinery to its cause.

To determine whether TIPE was merely a bystander or an active driver of this macrophage shift, the investigators combined bioinformatic analysis with laboratory experiments conducted both in cell culture and in living models. The results pointed clearly to a functional role. When TIPE levels rose, macrophages were pushed toward the M2 phenotype, adopting the marker profile and cytokine output that define tumor-promoting immune cells. Crucially, the team identified the intermediary in this process: decoy receptor 3, or DcR3, a secreted protein that TIPE upregulates. DcR3 earned its name because it acts as a molecular decoy, binding to signaling molecules that would otherwise alert the immune system and thereby dampening immune responses. The new work shows that in colorectal cancer, DcR3 is not just a passive suppressor of immune alerts but an active instructor of macrophage identity.

The mechanistic heart of the study lies in what happens after DcR3 is released into the tumor microenvironment. Using a series of binding and signaling experiments, the researchers demonstrated that DcR3 physically attaches to heparan sulfate proteoglycan 2, or HSPG2, a component of the extracellular matrix that surrounds cells. This interaction depends on heparan sulfate, a sugar chain modification carried by HSPG2. In other words, the sugar-decorated matrix protein serves as the docking station that allows DcR3 to engage its partner and transmit a signal into the macrophage. This level of molecular detail matters because it identifies specific points of contact that could, in principle, be targeted with drugs designed to interrupt the interaction.

Once DcR3 docks onto HSPG2, the signal that flows into the macrophage travels through one of the cell’s most well-known growth and survival pathways: the AKT signaling cascade, specifically through the protein kinase B alpha 1 isoform, AKT1. AKT1 activation is a classic pro-growth signal in many cell types, and the study shows that in macrophages it serves as the switch that drives M2 polarization directly. When the pathway is engaged, macrophages commit to the tumor-supportive M2 state, producing the cytokines and surface markers that suppress anti-tumor immunity. This finding ties together a long-recognized association between PI3K-AKT signaling and macrophage polarization with a specific upstream trigger that tumors can deploy at will.

But the story does not end with polarization alone. The researchers found that AKT1 activation also changes where macrophages go. Activated macrophages upregulate CXCL8, a chemokine, a type of signaling molecule that attracts cells bearing matching receptors. Through CXCL8, macrophages enhance their own chemotaxis and recruitment toward colorectal cancer cells, creating a self-reinforcing loop. Tumor-associated macrophages drawn into the tumor core become more numerous, more firmly embedded in the malignant tissue, and more committed to the M2 program. The tumor thus does not merely convert the immune cells that happen to be nearby; it actively broadcasts a signal that summons more macrophages and then converts them upon arrival. This dual effect, polarization plus recruitment, helps explain why high TIPE expression is associated with an immunosuppressive tumor microenvironment.

The experimental strategy underlying these conclusions combined several complementary approaches. Bioinformatic analysis of clinical data established the correlations between TIPE, DcR3-associated signaling, and M2 macrophage signatures in patient tumors. In vitro experiments using conditioned medium, the nutrient fluid in which cells have been grown, allowed the team to isolate the effects of tumor-derived factors on macrophage phenotype and to test the dependence of these effects on DcR3, HSPG2, heparan sulfate, and AKT1. In vivo models then provided the opportunity to observe the pathway operating within the complexity of a living system, where macrophages migrate, interact with multiple cell types, and respond to the full repertoire of tumor-derived signals. The convergence of evidence across these methods strengthens the case that the TIPE-DcR3-HSPG2-AKT1 axis is a genuine biological mechanism rather than a statistical coincidence.

The clinical implications of the work are twofold. First, the pathway offers potential diagnostic value. Because TIPE expression in tumor tissue tracks with the density and activity of M2 macrophages, measuring TIPE, or the M2 markers it induces, could help characterize the immune landscape of an individual patient’s tumor. In an era when immunotherapy success depends heavily on the state of the tumor microenvironment, such information could guide treatment decisions. Second, and perhaps more consequentially, each node in the identified pathway represents a candidate therapeutic target. Blocking the TIPE-driven upregulation of DcR3, interfering with the DcR3-HSPG2 interaction, disrupting heparan sulfate-dependent binding, or inhibiting AKT1 signaling in macrophages are all conceivable strategies for preventing the immune conversion that colorectal tumors rely upon. Existing drugs that target the broader PI3K-AKT pathway are already in clinical use for other cancers, which suggests that repurposing or refining such agents for macrophage-directed therapy in colorectal cancer is not an outlandish prospect.

Colorectal cancer remains a major global health burden, and while screening and surgical treatment have improved outcomes for many patients, advanced disease continues to claim a heavy toll. Immunotherapies that have transformed the treatment of some cancers have delivered more modest benefits in colorectal cancer overall, partly because many colorectal tumors are what oncologists describe as immunologically cold, lacking the inflamed, immune-cell-rich environment that checkpoint inhibitors require to work. Research that illuminates how tumors suppress and redirect immune cells therefore has value beyond the specific pathway involved. By showing that a single tumor-derived protein can orchestrate both the identity and the recruitment of macrophages through a defined molecular chain, this study adds a concrete mechanism to the growing understanding of how colorectal tumors build their protective microenvironment, and it hands researchers a map of specific, testable intervention points for future therapies.

The study, led by corresponding authors Yuhan Ye, Xingfeng Qiu, and Guohong Zhuang, with Shiying Zhang, Chunlin Shen, and Zeyang Lin as co-first authors, was conducted with ethical approval from Xiamen University and informed consent from all participants, and was supported by the National Natural Science Foundation of China along with provincial and municipal funding programs. As with any mechanistic study, the transition from laboratory findings to clinical application will require further validation, including the development of safe and effective ways to intervene in the pathway in patients. Nevertheless, by connecting TIPE, DcR3, HSPG2, heparan sulfate, AKT1, and CXCL8 into a single coherent signaling axis that governs macrophage polarization and recruitment, the research provides both a deeper understanding of colorectal cancer biology and a set of promising leads for the next generation of microenvironment-targeted treatments.

Subject of Research: TIPE-mediated DcR3 signaling driving M2 macrophage polarization in the colorectal cancer microenvironment

Article Title: The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer

Article References: Zhang, S., Shen, C., Lin, Z., Zhu, Q., Feng, Y., Sun, L., Zhang, C., Zhang, H., Wang, L., Chen, S., Huang, J., Ye, Y., Qiu, X., & Zhuang, G. (2026). The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer. Cancer Immunology, Immunotherapy, 75(10), Article 233. https://doi.org/10.1007/s00262-026-04531-8

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04531-8

Keywords: colorectal cancer, TIPE, DcR3, macrophage polarization, M2 macrophages, tumor microenvironment, HSPG2, AKT1 signaling, CXCL8, tumor immunology, immunosuppression, cancer immunotherapy